Prostate cancer is the most commonly diagnosed malignancy among men in industrialized
countries, accounting for the second leading cause of cancer-related deaths. Although we …

Emerging evidence indicates that metabolic dysregulation drives prostate cancer (PCa)
progression and metastasis. AMP-activated protein kinase (AMPK) is a master regulator of …

Although the role of metabolic syndrome (MS) and a high fat diet in prostate cancer (PCa)
risk is still a matter of intense debate, it is becoming increasingly clear that obesity can cause …

The androgen receptor (AR) is a key regulator of prostate growth and the principal drug
target for the treatment of prostate cancer. Previous studies have mapped AR targets and …

Cancer cells may overcome growth factor dependence by deregulating oncogenic and/or
tumor-suppressor pathways that affect their metabolism, or by activating metabolic pathways …

The androgen receptor (AR) plays a central role in prostate tumor growth. Inappropriate
reactivation of the AR after androgen deprivation therapy promotes development of …

Depletion of cellular energy activates the AMP-activated kinase (AMPK) to favor energy-
producing catabolic processes during tumorigenesis. Using a panel of in vitro cell lines and …

The molecular mechanisms underlying the development and progression of prostate cancer
are poorly understood. AMP-activated protein kinase (AMPK) is a serine-threonine kinase …

Abstract 5′ AMP‐activated kinase (AMPK) constitutes a hub for cellular metabolic and
growth control, thus representing an ideal therapeutic target for prostate cancers (PCas) …

Cellular transformation and cancer progression is accompanied by changes in the metabolic
landscape. Master co-regulators of metabolism orchestrate the modulation of multiple …